Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5301-5310 Newer>

Pharmaceutical Executive December 1, 2008 Walter Armstrong	The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future.
Pharmaceutical Executive December 1, 2008 Dave Ormesher	The Self-Fueling Marketing Machine Creating a self-fueling machine that produces data - which steers the marketing channel and in turn produces more data - represents the necessary evolution for the survival of pharmaceutical e-marketing.
Pharmaceutical Executive December 1, 2008 Sarah Houlton	Animal Humanity The new EU directive looks to reduce, refine, and eventually replace animal testing.
Pharmaceutical Executive December 1, 2008 Patrick Clinton	Reason to Believe Here are a few things to be optimistic about in the pharmaceutical industry.
Pharmaceutical Executive December 1, 2008 Jill Wechsler	Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers.
The Motley Fool December 9, 2008 Brian Orelli	Human Genome's Hep C Drug Is Halfway Home One trial down, one to go for Human Genome Sciences.
The Motley Fool December 9, 2008 Brian Orelli	The FDA Can't See the Forest or the Trees Forest Laboratories and Cypress Bioscience are still waiting for FDA approval, but now they've got more data to prove their point.
The Motley Fool December 9, 2008 Brian Orelli	FDA Dashes Amylin Investors' Hopes Shareholders are still waiting to hear how much longer it'll be before Amylin and Eli Lilly can submit the marketing application for the once-weekly version of diabetes drug Byetta.
The Motley Fool December 9, 2008 Brian Orelli	Presents or Coal From the FDA? Let's take a look at a few companies expecting FDA decisions this month and see whether they're more likely to get a present or a lump of coal in their marketing-application stockings.
The Motley Fool December 8, 2008 Brian Orelli	A Checkup for Makers of Asthma Drugs Because of recent events, GlaxoSmithKline, AstraZeneca, Novartis, and Schering-Plough all face extra scrutiny from the FDA.
<Older 5301-5310 Newer> Return to current articles.